Organization
Exclusive: Vertex drops AAV gene therapy research, tRNA therapy partnership
gene therapy, Dependovirus, Transfer RNA, Partnership, Industry, research, Safety
ElevAAte and the push for East Asian American leaders in biopharma
ElevAAte, biopharma, East Asian American, Leadership, leaders, Asian Americans, Mentorships, East Asian Americans, Ken Song
Biogen says Leqembi sales are improving slowly following lackluster launch
Leqembi, Biogen, Sales – occupational activity, Growth, Eisai, United States Food and Drug Administration, Improving (qualifier value)
Moderna expands effort to rein in costs in an uncertain environment
Moderna, Financial cost, Uncertainty, Environment
FDA delays PDUFA date for small biotech, raising questions about impact of agency cuts
United States Food and Drug Administration, PDUFA, Impact food supplement, Approved, Agencies, questions
FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill
United States Food and Drug Administration, Califf, Unspecified Abortion, Contraceptives, Oral, Accelerated, Artificial Intelligence, RIFs, Infrequent, Agencies
Caribou cuts 32% of staff, further purges pipeline to focus on 2 oncology CAR-T prospects
Reindeer, CAR-T, Staff, Neoplasms, Cell Therapy, Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010, Clustered Regularly Interspaced Short Palindromic Repeats, Leukemia, Myelocytic, Acute, United States Food and Drug Administration, 32%
Halozyme sues Merck over subcutaneous Keytruda as licensing talks fall through
Merck, Legal patent, Subcutaneous Keytruda, Halozyme
Thermo Fisher jumps on the US investment bandwagon with $2B in additional spending
United States, Investments, Manufacture, Martes pennanti, Science, development aspects, Thermo Fisher